Radiation as an immunological adjuvant: current evidence on dose and fractionation.
about
The potential of radiotherapy to enhance the efficacy of renal cell carcinoma therapyThe Concept of Hormesis in Cancer Therapy - Is Less More?Radiation for Awakening the Dormant Immune System, a Promising Challenge to be ExploredCombining radiation and immunotherapy: a new systemic therapy for solid tumors?Unlocking the combination: potentiation of radiation-induced antitumor responses with immunotherapyRadiation as immunomodulator: implications for dendritic cell-based immunotherapyFractionated Radiotherapy with 3 x 8 Gy Induces Systemic Anti-Tumour Responses and Abscopal Tumour Inhibition without Modulating the Humoral Anti-Tumour ResponseCombination Approaches with Immune-Checkpoint Blockade in Cancer TherapyUpdate on immune checkpoint inhibitors in gynecological cancersEarly gene expression analysis in 9L orthotopic tumor-bearing rats identifies immune modulation in molecular response to synchrotron microbeam radiation therapyCurrent clinical trials testing the combination of immunotherapy with radiotherapy.DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity.Differential expression of stress and immune response pathway transcripts and miRNAs in normal human endothelial cells subjected to fractionated or single-dose radiation.Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach.Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer.CD47 in the tumor microenvironment limits cooperation between antitumor T-cell immunity and radiotherapyNHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy.Cancer-associated fibroblasts from lung tumors maintain their immunosuppressive abilities after high-dose irradiation.Peripheral myeloid-derived suppressor and T regulatory PD-1 positive cells predict response to neoadjuvant short-course radiotherapy in rectal cancer patients.Mutations of the human interferon alpha-2b (hIFNα-2b) gene in cancer patients receiving radiotherapy.Stereotactic Body Radiation Therapy: A useful weapon in anticancer treatment.Ionizing radiation, ion transports, and radioresistance of cancer cellsStereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment.Trial Watch: Immunotherapy plus radiation therapy for oncological indications.Radiotherapy: Changing the Game in Immunotherapy.A Century of Radiation Therapy and Adaptive ImmunityImmune modulation and stereotactic radiation: improving local and abscopal responses.In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatmentImmunotherapy Combined with Large Fractions of Radiotherapy: Stereotactic Radiosurgery for Brain Metastases-Implications for Intraoperative Radiotherapy after Resection.Combining Oncolytic Adenovirus with Radiation-A Paradigm for the Future of Radiosensitization.Immunomodulatory effects of radiation: what is next for cancer therapy?Integrating immunotherapy into chemoradiation regimens for medically inoperable locally advanced non-small cell lung cancer.Fractionated radiotherapy combined with PD-1 pathway blockade promotes CD8 T cell-mediated tumor clearance for the treatment of advanced malignanciesDNA Damage and Repair Biomarkers of Immunotherapy Response.SBRT for lung oligometastases: Who is the perfect candidate?The antitumor immune response generated by fractionated radiation therapy may be limited by tumor cell adaptive resistance and can be circumvented by PD-L1 blockadeRadiotherapy effects on anti-tumor immunity: implications for cancer treatment.Tumor Induction in Mice After Localized Single- or Fractionated-Dose Irradiation: Differences in Tumor Histotype and Genetic Susceptibility Based on Dose Scheduling.Abscopal Effects: Case Report and Emerging Opportunities.
P2860
Q26783291-755C9923-6F8F-4AE3-9150-BBBABE868D36Q26800519-ADE6C5CA-75CD-4821-A887-D02EE155E909Q26865395-6719123A-7D5E-46EA-8A6D-A6D78747BCF4Q26991721-C76604A5-11DA-4E4C-A18C-6230DE541BE0Q27001216-53F1B6DF-13DF-4F3B-8C7C-51E141CDC27EQ27025756-B491AD4A-AADA-4CDF-958C-4533F9121D81Q27334088-85C1C8DB-4657-4A3D-B3AF-29DC68A53062Q28066199-12B7EE40-1E7A-4D58-AD12-5D0C2CC513DAQ28076497-1C7B81AC-1BE5-48FD-A99A-839FE284EE59Q28538112-73E72320-9BC7-4F7E-975A-7DC7BA12406AQ30356447-7380F859-2B7D-4391-ACC1-87C7B0467834Q33804663-186E1EA8-8951-4975-852E-ECD27E4DFD40Q33911452-2C6FB3CF-F372-4E1F-AC7C-4E0CD9A21E0EQ34172008-2DD41929-4FB8-4F61-B969-BB1FFE404311Q34196471-1FC78B5D-4A7E-4B2B-B58E-A6BC39758A3CQ34333155-2B36B31B-6368-41E0-8BAC-13B6FC42A848Q34621578-467DE43B-E013-4589-87C4-57D314137A62Q35059990-BB7FF0AF-4601-4C0D-A049-85FBA567D7C9Q35598951-620A70B0-401C-44C6-AEDF-9803765E8BCAQ35781562-AC235B3C-FF31-4FF3-B45B-FA53D636CCE1Q36057129-6C19BDC8-BDF3-4056-BB37-A68EFCE48F7FQ36323329-756F4D92-54FC-406B-83F3-200FD73546BAQ37095176-CB82C5B0-B720-4CE5-9782-2A0EAFDF527BQ37114644-92BD5A06-8CC0-42A1-B0AA-D568EE823D2FQ37308207-A4D98359-7823-430D-BAD2-839CE56C0B78Q37351338-232A65BD-D9CB-4644-AF53-B06062518237Q37747153-AB3B5E11-D8D8-401D-8961-BB344D7209FCQ38170122-219BA9C2-AAD6-47C6-BC3A-F5408D30F242Q38543250-725EC55D-A678-4583-8466-B90F44D4B997Q38632924-7D1961F4-2AEC-4AC6-AF1D-4B9D406D731DQ38645128-E0CC1167-019B-4895-B321-A04DCA6E803AQ38654155-DFB9AE45-47D1-4A38-9A96-AC4F9A7E9AC4Q38771934-A998ADF1-8AAB-4220-B1A7-4D8513DBE115Q38799946-F611B071-2E95-4B58-B53C-12F36DE5CA92Q39384263-46E44BA2-B29C-441E-A67B-A040FA21760BQ40179018-CA4C0E4C-1275-4B11-951D-BAC731C3F048Q40771053-A9C43DBF-5D84-409A-8A7F-C6B6FCDFDB21Q40914349-468E3ADD-0778-4E07-8D99-07547879D7CEQ41778571-FD03874A-D6F6-4576-A56D-C328F87490ACQ42222358-2A0D9C74-088F-4E4A-9ADC-8C401D2E0805
P2860
Radiation as an immunological adjuvant: current evidence on dose and fractionation.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Radiation as an immunological adjuvant: current evidence on dose and fractionation.
@ast
Radiation as an immunological adjuvant: current evidence on dose and fractionation.
@en
type
label
Radiation as an immunological adjuvant: current evidence on dose and fractionation.
@ast
Radiation as an immunological adjuvant: current evidence on dose and fractionation.
@en
prefLabel
Radiation as an immunological adjuvant: current evidence on dose and fractionation.
@ast
Radiation as an immunological adjuvant: current evidence on dose and fractionation.
@en
P2860
P356
P1476
Radiation as an immunological adjuvant: current evidence on dose and fractionation
@en
P2093
Silvia C Formenti
P2860
P356
10.3389/FONC.2012.00153
P577
2012-10-26T00:00:00Z